Kari Anne Sveen

Learn More
Our aims were to study left ventricular (LV) function and myocardial blood flow reserve (MBFR) in long-term type 1 diabetes and associations with advanced glycation end products (AGEs). A total of 20 type 1 diabetes patients from the Oslo Study without significant stenosis on coronary angiography were compared with 26 controls. LV systolic and diastolic(More)
Benfotiamine, a synthetic thiamine monophosphate analog with improved bioavailability compared with thiamine (1), has been shown to prevent the development of microvascular complications in rats without changes in glycemic control (2). Short-term studies (3–12 weeks) in humans have suggested that high-dose benfotiamine (up to 600 mg/day) can improve(More)
OBJECTIVE To study large- and small-nerve fiber function in type 1 diabetes of long duration and associations with HbA1c and the advanced glycation end products (AGEs) N-ε-(carboxymethyl)lysine (CML) and methylglyoxal-derived hydroimidazolone. RESEARCH DESIGN AND METHODS In a long-term follow-up study, 27 persons with type 1 diabetes of 40 ± 3 years(More)
AIMS To study intima media thickness (cIMT) and arterial stiffness in type 1 diabetes of long duration, and their associations with the collagen cross-linker glucosepane and inflammatory and oxidative markers. METHODS Twenty-seven individuals with type 1 diabetes mellitus of 40 years duration from the Oslo Study cohort and 24 age-matched controls were(More)
We welcome the commentary of Ziegler et al. (1) and are delighted to have the opportunity to clarify certain details of the study that were included in our first submission but had to be omitted because of article length restrictions. We don’t agree with the statement that because the number of subjects included with confirmed diabetic sensorimotor(More)
OBJECTIVE To study the effects of long-term oral benfotiamine supplementation on peripheral nerve function and soluble inflammatory markers in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS The study randomly assigned 67 patients with type 1 diabetes to receive 24-month benfotiamine (300 mg/day) or placebo supplementation. Peripheral nerve(More)
  • 1